Zilver® PTX® Leads to Fewer Complications and Shorter Hospital Stays Than Traditional Bypass Surgery

B2B Training: What’s the Most Effective Way of Learning?

B2B training, which is short for business-to-business training, is a popular and convenient type of training that enables entire companies to train their teams...

AlixPartners Forecasts: Household Products Could Cost U.S. Manufacturers and Consumers 15% More This Year Due to Resin Shortage

While companies can’t control the market forces at play, they can take action to mitigate the risk and impact of supply chain disruption.

At this year’s VEITHsymposium®, Dr. Marc Bosiers presented data that show that patient treatment with the Zilver® PTX® stent has several benefits when compared to traditional bypass surgery. The data, which were gathered from a randomized controlled trial, show that treatment with Zilver PTX results in fewer complications and shorter hospital stays for patients with peripheral artery disease (PAD).1

PAD affects more than 236 million people worldwide.2 Zilver PTX, Cook Medical’s paclitaxel-coated stent is used to treat patients with PAD. To better understand the impact of Zilver PTX, Cook Medical funded a five-year physician-sponsored study called ZILVERPASS that compared the effects of treatment with Zilver PTX to traditional open prosthetic bypass surgery. The study was a randomized, multicenter trial that involved 220 patients in four countries.

The data presented at VEITHsymposium show that the procedure with Zilver PTX takes about half the time as a bypass procedure. Patients who were treated with Zilver PTX had a hospital stay that was on average five days shorter. Thirty days after the procedure, patients who were treated with Zilver PTX for long and complex lesions were 60% less likely to have complications than patients who had bypass surgery. In addition, other clinical outcomes of Zilver PTX were comparable to those of bypass surgery, according to the two-year data. This study is continuing to collect results through five years.

“Our mission with Zilver PTX — and with every product we make at Cook Medical — is to try to improve people’s lives. Cook Medical has released extensive data around Zilver PTX, and this device continues to show benefits across a wide spectrum of patients. We hope that by continuing the conversation around paclitaxel, physicians and patients can make more informed decisions,” said Mark Breedlove, vice president of Cook Medical’s Vascular division.

If you have questions about Zilver PTX, please contact us at ZilverPTX@CookMedical.com, and a member of our team will respond within 24 hours. The VEITHsymposium presentation and additional Zilver PTX information are available at https://www.cookmedical.com/peripheral-intervention/paclitaxel/.

Note: Dr. Marc Bosiers is a paid consultant for Cook Medical.


References

spot_img

DON'T MISS

Mediclinic Appoints 2 New Independent Non-Executive Directors

Natalia Barsegiyan and Zarina Bassa will bring significant and diverse skills and experience, complementing those of existing Board members. I am confident they will both be great additions to our Board of Directors.”

Asensus Surgical Appoints Two New Board Members

Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced the expansion of its Board of Directors, appointing...

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.